Generally, mutations in GBA1 are associated with a more severe clinical progression, including earlier age of onset, earlier and more severe cognitive impairment with a shorter time to dementia and higher frequency of neuropsychiatric symptoms compared to idiopathic PD2–7. Here, GBA1 is linked to dementia.